{
  "nctId": "NCT02741700",
  "briefTitle": "SToRytelling to Improve DiseasE Outcomes in GOut: The STRIDE-GO2 Study",
  "officialTitle": "STorytelling to Improve DiseasE Outcomes in GoUT: The STRIDE-GO Study",
  "protocolDocument": {
    "nctId": "NCT02741700",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2018-05-22",
    "uploadDate": "2021-12-06T13:13",
    "size": 255387,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02741700/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 306,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-05-31",
    "completionDate": "2021-08-31",
    "primaryCompletionDate": "2020-12-31",
    "firstSubmitDate": "2016-03-21",
    "firstPostDate": "2016-04-18"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* African American Veteran Patients with Gout currently on urate-lowering therapy (ULT; most commonly allopurinol) with either low ULT adherence, defined as an average medication possession ration (MPR) \\<0.80 or MPR \\>=0.80\n\nExclusion Criteria:\n\n* participants who use pill-box for ULT medication use\n* participants who Opt-out for the research will not be contacted",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "19 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Medication Adherence",
        "description": "ULT adherence, directly measured by using MEMS (Medication Event Monitoring System) Caps at 3, 6, and 9 months (assess intervention's effect) and 12 months (assess the durability of effect)",
        "timeFrame": "3, 6, 9, and 12 months"
      }
    ],
    "secondary": [
      {
        "measure": "Gout Flares",
        "description": "Participant-reported total number of gout flares in the last 1 month",
        "timeFrame": "12 months"
      },
      {
        "measure": "Patient Satisfaction",
        "description": "Patient satisfaction with medication on the patient questionnaire (SATMED composite score), range 0-100. The SATMED-Q contains 17 items, each scored on a 5-point Likert scale. The total composite score ranges between 0 and 68. The score was converted to a percentage as recommended (=(raw score\\*100)/68); higher score = more satisfaction with medication.",
        "timeFrame": "12 months"
      },
      {
        "measure": "Target Serum Urate",
        "description": "Serum urate with absolute value in mg/dl, as indirect measures of better ULT adherence and important gout outcomes",
        "timeFrame": "12 months"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 3,
      "otherCount": 0,
      "totalCount": 4
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 39,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:57.683Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}